WSB Rally Adaptimmune Therapeutics Sees 1,314% Discussion Spike

Sep 16, 2025 - Adaptimmune Therapeutics (ADAP) has captured significant attention on WallStreetBets, experiencing a remarkable 1,314% increase in discussion mentions. Meanwhile, Opendoor Technologies also stands out, driven by recent leadership changes and a 37% stock surge. These developments underscore the dynamic shifts in market sentiment and highlight the blend of optimism and caution among investors.

Here's a closer look at what's fueling the attention around these trending stocks:

Opendoor's Stock Surge Driven by Leadership Changes


Opendoor Technologies (NASDAQ: OPEN) has recently experienced a notable surge in discussion popularity, with 258 mentions on WallStreetBets, despite a -15% change in its mention trend. The stock jumped 37% last week following the announcement of Kaz Nejatian, formerly COO of Shopify, as the new CEO. This leadership change, alongside the return of co-founders Keith Rabois and Eric Wu to the board, has spurred optimism among retail and activist investors, who are hopeful for a turnaround amid ongoing struggles in the housing market exacerbated by high mortgage rates.

Analysts hold a mixed view on Opendoor's prospects. While some are optimistic about the potential for operational improvements under new leadership, the overarching sentiment remains cautious. With the stock still trading at significant discounts to its all-time highs and analysts issuing a consensus rating of “Hold,” concerns persist regarding the company's ability to sustain gains in a challenging environment. Most forecasts indicate a potential downside, with an average price target around $1.11, highlighting skepticism about the disconnect between the stock's current valuation and its underlying fundamentals.

loanDepot Sees Surge in Stock Discussion Popularity


loanDepot (LDI) has recently experienced a notable increase in discussion on platforms like WallStreetBets, with 258 mentions despite a -36% change in its trend. This uptick can be attributed to the announcement of substantial inducement grants for key executives, including 2,000,000 performance share units (PSUs) tied to specific stock price targets, which aligns executive compensation with the company’s performance. Additionally, the firm’s recent financial maneuvers, including a successful $150 million private offering and strategic debt management, have sparked investor interest.

Analyst sentiment on loanDepot's stock is mixed. While UBS has raised its price target from $1.40 to $1.90, indicating cautious optimism about the company’s potential, other analysts maintain a neutral stance. The stock's recent volatility, combined with insider trading activities, suggests a level of uncertainty among investors. Overall, the discussion around loanDepot reflects a blend of enthusiasm for its strategic initiatives and skepticism about sustaining its recent gains in the competitive mortgage market.

Tesla Stock Surges in Popularity Amid Musk's Confidence Boost


The recent spike in Tesla's (TSLA) discussion level, despite a notable decline in WallStreetBets mentions, can be attributed to CEO Elon Musk's significant $1 billion stock purchase, his largest since 2020. Musk's commitment to the company, highlighted by his statement about "burning the midnight oil," positions him as a strong advocate for Tesla, even as the company faces challenges like lagging vehicle registrations in China and ongoing investigations regarding safety concerns. The market reacted positively, with shares rising over 2% following Musk's announcement, signaling investor confidence in his leadership and future prospects.

Analysts exhibit a mixed sentiment regarding Tesla stock. While the consensus rating remains a "Hold," several analysts, including Dan Ives from Wedbush, express a bullish outlook, driven by the potential of Tesla's robotaxi ambitions and advancements in AI technology. However, caution is advised due to concerns over sales performance and Musk's controversial political engagement, which may impact brand perception. The average price target among analysts suggests a potential decline from current levels, reflecting skepticism about the sustainability of the recent gains.

Oracle (ORCL) Soars in WallStreetBets Mentions Amid AI Boom


Oracle's stock has gained significant traction on WallStreetBets, with a remarkable 219% increase in mentions, reflecting a growing enthusiasm for its role in the booming artificial intelligence sector. Recent reports highlight Oracle's strategic positioning as a key player in AI cloud computing, particularly through its partnership with Bloom Energy to supply fuel cell technology for AI data centers. Additionally, Oracle's involvement in the potential TikTok deal has further captured investor interest, signaling its increasing relevance in high-stakes technology ventures.

Analysts are largely bullish on Oracle's prospects, with many viewing it as a "unique megacap AI winner." The company has demonstrated substantial growth in its cloud infrastructure, boasting a forecasted revenue increase of 77% for the current fiscal year. Analyst sentiment remains positive, with a consensus rating of "Strong Buy" and price targets suggesting potential upside of approximately 16.62%. This optimism is driven by Oracle's robust backlog of contracted revenue and its significant investments in AI-driven initiatives, which position it favorably against competitors in the rapidly evolving tech landscape.

Adaptimmune Therapeutics (ADAP) Soars in Discussion Popularity


Adaptimmune Therapeutics has recently experienced a remarkable surge in discussions, with 198 mentions on WallStreetBets reflecting a staggering 1,314% increase in its trend. The stock's price jumped by 27.47% to $0.08 amid rising interest in the company's innovative T-cell therapies, particularly after reports of a pivotal Phase II trial achieving primary endpoints with its investigational product, lete-cel. This positive development in the clinical stage has positioned Adaptimmune favorably within the rapidly growing cellular immunotherapy market, attracting attention from both retail investors and the broader financial community.

Analysts maintain a bullish stance on ADAP, with a consensus price target suggesting a potential upside of approximately 1,564.6% from its current price. This optimism is driven by the anticipated growth in the cellular immunotherapy sector, underscored by increasing research and successful clinical trials in treating solid tumors. However, some caution arises from recent reports of Nasdaq delisting concerns due to low market capitalization, which could dampen investor sentiment if not addressed promptly. Overall, the sentiment remains predominantly positive, supported by strong clinical advancements and investor interest.

Beyond the five most mentioned stocks on WSB, noteworthy trends include Adaptimmune Therapeutics with a staggering 1,314% increase, and BigBear.ai with a 600% jump. Oracle saw a 219% rise, while Novo Nordisk and CLEAR Secure experienced 157% and 111% increases, respectively. Meanwhile, aTyr Pharma dropped by -83%, Rocket Companies rose by 69%, Tesla fell by -68%, bioAffinity Technologies decreased by -60%, and Snap increased by 57%.